Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2012 /
Advances in advanced renal cell carcinoma from ESMO 2012: Part 2

28th Sep - 2nd Oct 2012

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 13.10.12
Views: 4982
Rating:

Prof Tim Eisen - Addenbrooke's Oncology Centre, Cambridge, Prof Bernard Escudier - Institut Gustave Roussy, France, Dr Thomas Powles - St Bartholomew Hospital, London, Dr Thomas Hutson - Baylor Sammons Cancer Center, USA

Professor Tim Eisen from Addenbrooke's Oncology Centre, Cambridge, talks to ecancer TV with Dr Bernard Escudier from Institut Gustave Roussy, France, Dr Thomas Powles from St Bartholomew Hospital, London, and Dr Thomas Hutson from Baylor Sammons Cancer Center, USA. The experts outline results from the major studies reporting at ESMO 2012 in mRCC. 

 

The panel discuss second-line therapies, Dr Poles outlines new data presented from the INTORSECT study with sorafenib and temsirolimus in terms of effects on PFS, and the potential rationale for usingVEGF inhibition vs. MTOR inhibition.  This leads to a panel discussion of the potential place of MTOR inhibitors, and the potential impact of the latest data on clinical practice. 

 

This programme has been supported by an educational grant from GlaxoSmithKline.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation